/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the development and commercialization of innovative therapies for diseases such as HIV, liver diseases, cancer, and inflammation. Its market cap currently stands at $114.2 billion. The company is set to announce its fiscal Q4 earnings results after the market closes on Tuesday, February 11.
Ahead of the event, analysts expect GILD to report a profit of $1.67 per share, down 2.9% from $1.72 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in three of the past four quarters and missed on another occasion.